Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avdoralimab + Durvalumab in Advanced Solid Tumors
NCT03665129Phase 1Terminated
- Sponsor
- Innate Pharma
- Start
- Sep 2018
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of avdoralimab in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) (4 arms), sponsored by Innate Pharma. Primary endpoints: Occurrence of Drug Limited Toxicities up to 6 weeks and Adverse Events. Started Sep 2018; status: terminated.
02
Drugs
avdoralimab
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03665129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03665129.